Lexaria Bioscience Corp. Segments Disclosure
15. Segment Information
The Company has one reportable segment: IP licensing. The IP licensing segment generates revenue from customers by licensing its proprietary DehydraTECH technology.
The IP licensing segment’s accounting policies are the same as those described in the summary of significant accounting policies at Note 2.
The chief operating decision maker, our Chief Executive Officer, assesses performance of the IP Licensing segment and makes resource allocation decisions based on cash flows that are also reported on the Consolidated Statements of Cash Flows.
The measure of segment assets is reported on the balance sheet as consolidated total assets.
The measure of segment profit or loss is net loss as per the Consolidated Statements of Operations and Comprehensive Loss.
The Company invested in additional intellectual property and purchases of equipment totaling $75,106 and $24,646 respectively, during the fiscal year ended August 31, 2025, and $145,591 and $43,014, respectively, during the fiscal year ended August 31, 2024. The following table details losses for the IP licensing segment, as well as reconciliations to consolidated net loss for the years ended August 31, 2025 and August 31, 2024.
|
| Year Ended August 31, |
| |||||
IP Licensing Segment |
| 2025 |
|
| 2024 |
| ||
Licensing revenue |
| $ | 696,000 |
|
| $ | 457,990 |
|
less: |
|
|
|
|
|
|
|
|
Research and Development |
|
| 8,238,757 |
|
|
| 2,360,565 |
|
Consulting |
|
| 564,618 |
|
|
| 1,029,140 |
|
Wages & Salaries |
|
| 1,706,410 |
|
|
| 791,831 |
|
Legal and professional |
|
| 435,537 |
|
|
| 595,258 |
|
Accounting and audit |
|
| 197,312 |
|
|
| 216,808 |
|
Advertising and promotions |
|
| 408,367 |
|
|
| 632,597 |
|
Investor relations |
|
| - |
|
|
| 79,900 |
|
Depreciation and amortization |
|
| 87,825 |
|
|
| 76,153 |
|
Office and miscellaneous (a) |
|
| 628,089 |
|
|
| 332,990 |
|
Travel |
|
| 56,451 |
|
|
| 38,384 |
|
Impairment loss |
|
| 247,364 |
|
|
| 57,836 |
|
Other income (loss) |
|
| (30,697 | ) |
|
| (55,524 | ) |
Segment net loss |
| $ | (11,905,427 | ) |
| $ | (5,808,996 | ) |
Reconciliation of profit and loss: |
|
|
|
|
|
| ||
B2B revenue |
|
| 9,923 |
|
|
| 6,288 |
|
B2B cost of sales |
|
| 2,720 |
|
|
| 4,822 |
|
B2B operating expenses |
|
| 13,210 |
|
|
| 1,124 |
|
Consolidated net loss |
| $ | (11,911,434 | ) |
| $ | (5,808,654 | ) |
(a) Office and miscellaneous expense includes office expense, insurance expense, foreign currency exchange gains and losses, bad debt, and other overhead expenses.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Nov 28, 2025 | Showing above |
| 2024 | Nov 26, 2024 | |
| 2023 | Nov 20, 2023 | |
| 2022 | Nov 28, 2022 | |
| 2021 | Nov 29, 2021 | |
| 2020 | Oct 15, 2020 | |
| 2019 | Nov 14, 2019 | |
| 2018 | Nov 14, 2018 | |
| 2017 | Nov 27, 2017 | |
| 2016 | Nov 29, 2016 | |
| 2015 | Nov 27, 2015 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.